Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313382983> ?p ?o ?g. }
Showing items 1 to 68 of
68
with 100 items per page.
- W4313382983 endingPage "136.18" @default.
- W4313382983 startingPage "136.18" @default.
- W4313382983 abstract "Abstract The immunosuppressive tumor microenvironment dampens host antitumor immunity by multiple mechanisms including interfering with various cell signaling pathways that aid in the differentiation and function of immune cells. We have taken an immunotherapeutic approach in order to strengthen antitumor immunity in mice bearing solid tumors, specifically breast tumors. In doing so, we observed that treatment with bortezomib, an FDA-approved proteasome inhibitor, has the ability to increase CD8+T lymphocyte IFNγ secretion and expression of effector molecules, perforin, granzyme-B and the T-box transcription factor eomesodermin. In order to understand the molecular mechanism(s) of how bortezomib works to improve antitumor immunity we sought to explore its effects on miRNA expression as well as function. We found that treatment of wild-type or tumor-bearing BALB/c mice with bortezomib modulated the expression of various miRNAs in CD8+T cells. From miRNA array data, we identified miR-155 as one prominent modulator of antitumor CD8+T cell immune functions. miR-155 has been accredited to controlling CD8+T cell responses by regulating interferon signaling in viral infections and cancer. We are currently elucidating the mechanisms of bortezomib-mediated effects on miR-155 and its targets, such as suppressor of cytokine signaling 1 (SOCS1) and inositol polyphosphate-5-phosphatase (SHIP1) that are associated with T cell function. These data provide novel insights on using bortezomib not only as an agent to sensitize tumors to cell death, but also to provide lymphocyte-stimulatory effects that could overcome immunosuppressive actions of tumor on antitumor T cell function." @default.
- W4313382983 created "2023-01-06" @default.
- W4313382983 creator A5018027155 @default.
- W4313382983 creator A5019557489 @default.
- W4313382983 creator A5033716816 @default.
- W4313382983 creator A5044520462 @default.
- W4313382983 creator A5051469676 @default.
- W4313382983 date "2019-05-01" @default.
- W4313382983 modified "2023-10-16" @default.
- W4313382983 title "Bortezomib improves antitumor CD8+ T cell function by modulating miR-155 and its targets" @default.
- W4313382983 doi "https://doi.org/10.4049/jimmunol.202.supp.136.18" @default.
- W4313382983 hasPublicationYear "2019" @default.
- W4313382983 type Work @default.
- W4313382983 citedByCount "0" @default.
- W4313382983 crossrefType "journal-article" @default.
- W4313382983 hasAuthorship W4313382983A5018027155 @default.
- W4313382983 hasAuthorship W4313382983A5019557489 @default.
- W4313382983 hasAuthorship W4313382983A5033716816 @default.
- W4313382983 hasAuthorship W4313382983A5044520462 @default.
- W4313382983 hasAuthorship W4313382983A5051469676 @default.
- W4313382983 hasConcept C154317977 @default.
- W4313382983 hasConcept C167672396 @default.
- W4313382983 hasConcept C183193105 @default.
- W4313382983 hasConcept C202751555 @default.
- W4313382983 hasConcept C203014093 @default.
- W4313382983 hasConcept C2776062744 @default.
- W4313382983 hasConcept C2776090121 @default.
- W4313382983 hasConcept C2776364478 @default.
- W4313382983 hasConcept C2777478702 @default.
- W4313382983 hasConcept C2780380082 @default.
- W4313382983 hasConcept C502942594 @default.
- W4313382983 hasConcept C55493867 @default.
- W4313382983 hasConcept C86803240 @default.
- W4313382983 hasConcept C8891405 @default.
- W4313382983 hasConceptScore W4313382983C154317977 @default.
- W4313382983 hasConceptScore W4313382983C167672396 @default.
- W4313382983 hasConceptScore W4313382983C183193105 @default.
- W4313382983 hasConceptScore W4313382983C202751555 @default.
- W4313382983 hasConceptScore W4313382983C203014093 @default.
- W4313382983 hasConceptScore W4313382983C2776062744 @default.
- W4313382983 hasConceptScore W4313382983C2776090121 @default.
- W4313382983 hasConceptScore W4313382983C2776364478 @default.
- W4313382983 hasConceptScore W4313382983C2777478702 @default.
- W4313382983 hasConceptScore W4313382983C2780380082 @default.
- W4313382983 hasConceptScore W4313382983C502942594 @default.
- W4313382983 hasConceptScore W4313382983C55493867 @default.
- W4313382983 hasConceptScore W4313382983C86803240 @default.
- W4313382983 hasConceptScore W4313382983C8891405 @default.
- W4313382983 hasIssue "1_Supplement" @default.
- W4313382983 hasLocation W43133829831 @default.
- W4313382983 hasOpenAccess W4313382983 @default.
- W4313382983 hasPrimaryLocation W43133829831 @default.
- W4313382983 hasRelatedWork W1969504080 @default.
- W4313382983 hasRelatedWork W1983122232 @default.
- W4313382983 hasRelatedWork W1983832284 @default.
- W4313382983 hasRelatedWork W2017949628 @default.
- W4313382983 hasRelatedWork W2058581379 @default.
- W4313382983 hasRelatedWork W2088194175 @default.
- W4313382983 hasRelatedWork W2225380758 @default.
- W4313382983 hasRelatedWork W2908606283 @default.
- W4313382983 hasRelatedWork W4313354898 @default.
- W4313382983 hasRelatedWork W4353015211 @default.
- W4313382983 hasVolume "202" @default.
- W4313382983 isParatext "false" @default.
- W4313382983 isRetracted "false" @default.
- W4313382983 workType "article" @default.